How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.

Breakdown:
Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 to 35.53 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 1,312.79 Cr to 2,034.25 Cr, and total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, indicating a robust growth in the company's financial position. Cash flow from operating activities showed a slight decline from 265.00 Cr in Mar'24 to 244.00 Cr in Mar'25, while net cash outflow was recorded at -14.00 Cr in Mar'25, down from a positive inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and asset base, although cash flow management appears to have faced some challenges in the latest fiscal year.